Peter Y. Zhao

Peter Y. Zhao

Auto-generated profile, based on publicly available information

Peter Y. Zhao

Department of Ophthalmology, New England Eye Center, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
PZPeter Y. Zhao
Peter Y. Zhao
RRRaheem Rahmathullah
Raheem Rahmathullah
BSBrian Stagg
Brian Stagg
FAFaisal A Almobarak
Faisal A Almobarak
DEDeepak P. Edward
Deepak P. Edward
JSJoshua D. Stein
Joshua D. Stein
Importance Medical and surgical interventions for glaucoma are effective only if they are affordable to patients. Little is known about how affordable glaucoma interventions are in developing and developed countries. Objective To compare the prices of topical glaucoma medications, laser trabeculoplasty, and trabeculectomy relative with median annual household income (MA-HHI) for countries worldwide. Design, Setting and Participants Cross-sectional observational study. For each country, we obtained prices for glaucoma medications, laser trabeculoplasty, and trabeculectomy using government pricing data, drug databases, physician fee schedules, academic publications, and communications with local ophthalmologists. Prices were adjusted for purchasing power parity and inflation to 2016 US dollars, and annual therapy prices were examined relative to the MA-HHI. Interventions costing less than 2.5% of the MA-HHI were considered affordable. Main Outcomes and Measures Daily cost for topical glaucoma medications, cost of annual therapy with glaucoma medications, laser trabeculoplasty, and trabeculectomy relative to MA-HHI in each country. Results Data were obtained from 38 countries, including 17 developed countries and 21 developing countries, as classified by the World Economic Outlook. We observed considerable variability in intervention prices compared with MA-HHI across the countries and across interventions, ranging from 0.1% to 5% of MA-HHI for timolol, 0.1% to 27% for latanoprost, 0.2% to 17% for laser trabeculoplasty, and 0.3% to 42% for trabeculectomy. Timolol was the most affordable medication in all countries studied and was 2.5% or more of MA-HHI in only 2 countries (5%). The annual cost of latanoprost was 2.5% or more of MA-HHI in 15 countries (41%) (15 developing countries [75%] and no developed countries). The cost of laser trabeculoplasty was 2.5% or more of the MA-HHI in 15 countries (44%) (11 developing countries [65%] and 4 developed countries [24%]). The cost of trabeculectomy was 2.5% or more of the MA-HHI in 28 countries (78%) (18 developing countries [95%] and 10 developed countries [59%]). In 18 countries (53%), laser trabeculoplasty cost less than a 3-year latanoprost supply. Conclusions and Relevance For many patients worldwide, the costs of medical, laser, and incisional surgical interventions were 2.5% or more of the MA-HHI. Successfully reducing global blindness from glaucoma requires addressing multiple contributing factors, including making glaucoma interventions more affordable.

26 May 2022 in Ophthalmology Retina
Verified
Journal Article
Closed access
PZPeter Y. Zhao
Peter Y. Zhao
KBKari Branham
Kari Branham
DSDana Schlegel
Dana Schlegel
AFAbigail T. Fahim
Abigail T. Fahim
KJK. Thiran Jayasundera
K. Thiran Jayasundera

9 October 2023 in Ophthalmology Retina
Verified
Journal Article
Closed access
NBNikhil Bommakanti
Nikhil Bommakanti
JCJonathan T. Caranfa
Jonathan T. Caranfa
BYBenjamin K. Young
Benjamin K. Young
PZPeter Y. Zhao
Peter Y. Zhao

27 October 2026 in Ophthalmology Science
Verified
Journal Article
Open access
YHYunchan Hwang
Yunchan Hwang
MJMuhammad Usman Jamil
Muhammad Usman Jamil
HTHiroyuki Takahashi
Hiroyuki Takahashi
AMAnna Marmalidou
Anna Marmalidou
JWJungeun Won
Jungeun Won
PZPeter Y. Zhao
Peter Y. Zhao